project id: TCGA-KIRC; case submitter id: TCGA-B8-A7U6; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.72; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.54; rna integrity number: 8.9; age at index: 54; days to birth: -19803; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1959; age at diagnosis: 19803; ajcc clinical m: M0; ajcc pathologic n: NX; ajcc pathologic stage: Stage I; ajcc pathologic t: T1a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 495.0; icd 10 code: C64.9; last known disease status: not reported; morphology: 8310/3; primary diagnosis: Clear cell adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Kidney, NOS; synchronous malignancy: No; tissue or organ of origin: Kidney, NOS; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 57; days to sample procurement: 0; initial weight: 190.0; portion submitter id: TCGA-B8-A7U6-01A-12; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 2.0; percent necrosis: 15.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 60.0; percent tumor nuclei: 90.0;